Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
This is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significa...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-05-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00209/full |
| _version_ | 1830489794720825344 |
|---|---|
| author | Adriano Aquino Guilherme L. Alexandrino Paul C. Guest Fabio Augusto Alexandre F. Gomes Michael Murgu Johann Steiner Johann Steiner Daniel Martins-de-Souza Daniel Martins-de-Souza Daniel Martins-de-Souza |
| author_facet | Adriano Aquino Guilherme L. Alexandrino Paul C. Guest Fabio Augusto Alexandre F. Gomes Michael Murgu Johann Steiner Johann Steiner Daniel Martins-de-Souza Daniel Martins-de-Souza Daniel Martins-de-Souza |
| author_sort | Adriano Aquino |
| collection | DOAJ |
| description | This is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significant improvement in positive and negative symptoms for 34 patients with little or no improvement for 20 patients. In addition, 37 patients showed an increase in body mass index after the 6 week treatment period, consistent with effects on metabolism and the association of such effects with symptom improvement. Profiling of plasma samples taken prior to therapy using liquid chromatography tandem mass spectrometry (LC-MS/MS) resulted in identification of 38, 10, and 52 compounds associated with the olanzapine, risperidone, and quetiapine treatment groups, which could be used to distinguish responders from non-responders. Limitations include the retroactive active nature of the study and the small sample size. Further investigations with larger sample sets could lead to the development of a molecular test that could be used to help psychiatrists determine the best treatment options for each patient. |
| first_indexed | 2024-12-21T19:42:56Z |
| format | Article |
| id | doaj.art-8438fb3e4475463390823efdd020836d |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-21T19:42:56Z |
| publishDate | 2018-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-8438fb3e4475463390823efdd020836d2022-12-21T18:52:24ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402018-05-01910.3389/fpsyt.2018.00209344963Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia PatientsAdriano Aquino0Guilherme L. Alexandrino1Paul C. Guest2Fabio Augusto3Alexandre F. Gomes4Michael Murgu5Johann Steiner6Johann Steiner7Daniel Martins-de-Souza8Daniel Martins-de-Souza9Daniel Martins-de-Souza10Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, BrazilGas Chromatography Laboratory, Chemistry Institute, University of Campinas, Campinas, BrazilLaboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, BrazilGas Chromatography Laboratory, Chemistry Institute, University of Campinas, Campinas, BrazilMass Spectrometry Applications & Development Laboratory Waters Corporation, São Paulo, BrazilMass Spectrometry Applications & Development Laboratory Waters Corporation, São Paulo, BrazilDepartment of Psychiatry and Psychotherapy, University of Magdeburg, Magdeburg, GermanyCenter for Behavioral Brain Sciences, Magdeburg, GermanyLaboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, BrazilUNICAMP's Neurobiology Center, Campinas, BrazilInstituto Nacional de Biomarcadores em Neuropsiquiatria (INBION), Conselho Nacional de Desenvolvimento Científico e TecnológicoSão Paulo, BrazilThis is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significant improvement in positive and negative symptoms for 34 patients with little or no improvement for 20 patients. In addition, 37 patients showed an increase in body mass index after the 6 week treatment period, consistent with effects on metabolism and the association of such effects with symptom improvement. Profiling of plasma samples taken prior to therapy using liquid chromatography tandem mass spectrometry (LC-MS/MS) resulted in identification of 38, 10, and 52 compounds associated with the olanzapine, risperidone, and quetiapine treatment groups, which could be used to distinguish responders from non-responders. Limitations include the retroactive active nature of the study and the small sample size. Further investigations with larger sample sets could lead to the development of a molecular test that could be used to help psychiatrists determine the best treatment options for each patient.https://www.frontiersin.org/article/10.3389/fpsyt.2018.00209/fullschizophreniadrug responseantipsychoticslipidomicsbiomarkers |
| spellingShingle | Adriano Aquino Guilherme L. Alexandrino Paul C. Guest Fabio Augusto Alexandre F. Gomes Michael Murgu Johann Steiner Johann Steiner Daniel Martins-de-Souza Daniel Martins-de-Souza Daniel Martins-de-Souza Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients Frontiers in Psychiatry schizophrenia drug response antipsychotics lipidomics biomarkers |
| title | Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients |
| title_full | Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients |
| title_fullStr | Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients |
| title_full_unstemmed | Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients |
| title_short | Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients |
| title_sort | blood based lipidomics approach to evaluate biomarkers associated with response to olanzapine risperidone and quetiapine treatment in schizophrenia patients |
| topic | schizophrenia drug response antipsychotics lipidomics biomarkers |
| url | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00209/full |
| work_keys_str_mv | AT adrianoaquino bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT guilhermelalexandrino bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT paulcguest bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT fabioaugusto bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT alexandrefgomes bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT michaelmurgu bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT johannsteiner bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT johannsteiner bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT danielmartinsdesouza bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT danielmartinsdesouza bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients AT danielmartinsdesouza bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients |